Gaurav Joshi* and Ramarao Poduri* Pages 610 - 619 ( 10 )
Background: The rapid spread of SARS-CoV-2 has caused havoc and panic among individuals, which has further worsened due to the unavailability of a proven drug(s) regime.
Objective: The current work involves drug repurposing from the pool of USFDA approved drugs involving in silico virtual screening technique against COVID-19.
Materials and Methods: Methodology involves virtual screening of 8548 FDA approved drugs against target protein endoribonuclease NendoU (Nsp15) (PDB ID: 6VWW).
Result: Virtual screening-based analysis enabled us to identify four drugs, Eprosartan, Inarigivir soproxil, Foretinib, and DB01813 that could plausibly target Nsp15 against COVID-19 disease.
Conclusion: The work offers the scope to corroborate the findings via in vitro and in vivo techniques to identify the potential of selected leads against COVID-19. The outcome may also help in tracing their molecular mechanism(s) in addition to their development at the clinical level in the future.
SARS-CoV-2, COVID-19, antiviral agents, drug repurposing, Nsp15, virtual screening, molecular modelling.
Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 15100, Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 15100